Detalles de la búsqueda
1.
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Ann Hepatol
; 20: 100257, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949786
2.
Glecaprevir/pibrentasvir for 8â¯weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
J Hepatol
; 72(3): 441-449, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31682879
3.
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Clin Gastroenterol Hepatol
; 18(11): 2544-2553.e6, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32621971
4.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28842997
5.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Antimicrob Agents Chemother
; 60(2): 1106-13, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26643326
6.
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Hepatology
; 61(5): 1523-32, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25644279
7.
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Hepatology
; 62(4): 1037-46, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26147154
8.
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology
; 147(2): 359-365.e1, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24818763
9.
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
J Hepatol
; 70(5): 1019-1023, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30857780
10.
Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis.
J Cyst Fibros
; 22(6): 1017-1023, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880023
11.
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Adv Ther
; 34(6): 1449-1465, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28536999
12.
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Clin Pharmacokinet
; 56(2): 153-163, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27389403
13.
Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
Antivir Ther
; 21(8): 707-714, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27584548
14.
Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Clin Ther
; 37(11): 2560-71, 2015 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26505529
15.
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
J Infect
; 70(2): 197-205, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25246359
16.
Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial.
Arq Gastroenterol
; 49(1): 56-63, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22481687
Resultados
1 -
16
de 16
1
Próxima >
>>